Group A *Streptococcus* encounters with host macrophages

J Andrés Valderrama¹ & Victor Nizet^{*,1,2}

¹Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA

²Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093, USA

* Author for correspondence: vnizet@ucsd.edu

Group A *Streptococcus* (GAS) is a leading human bacterial pathogen with diverse clinical manifestations. Macrophages constitute a critical first line of host defense against GAS infection, using numerous surface and intracellular receptors such as Toll-like receptors and inflammasomes for pathogen recognition and activation of inflammatory signaling pathways. Depending on the intensity of the GAS infection, activation of these signaling cascades may provide a beneficial early alarm for effective immune clearance, or conversely, may cause hyperinflammation and tissue injury during severe invasive infection. Although traditionally considered an extracellular pathogen, GAS can invade and replicate within macrophages using specific molecular mechanisms to resist phagolysosomal and xenophagic killing. Unraveling GAS–macrophage encounters may reveal new treatment options for this leading agent of infection-associated mortality.

First draft submitted: 10 July 2017; Accepted for publication: 5 September 2017; Published online: 11 December 2017

Keywords: Group A *Streptococcus* (GAS) • IL-1 β signaling • intracellular survival • macrophage • NLRP3 inflammasome • phagocytosis • Toll-like receptors • xenophagy

The Gram-positive bacterium *Streptococcus pyogenes*, or group A *Streptococcus* (GAS), is a leading human pathogen, responsible for disease conditions ranging from mild infections, such as pharyngitis and impetigo, to invasive diseases, including necrotizing fasciitis (NF) and streptococcal toxic-shock syndrome. Serious immune sequelae may be triggered after repeated GAS infections, including acute glomerulonephritis and rheumatic heart disease [1,2]. The estimated number of people suffering from serious GAS disease includes 1.8 million new cases each year, accounting for 517,000 deaths annually, placing GAS among the 10 major causes of human infection-associated mortality [3,4]. During recent decades, significant progress has been made in understanding the molecular mechanisms of GAS disease pathogenesis. GAS expresses a multitude of surface-bound and secreted virulence factors that are variably expressed among strains and underlie differential host susceptibilities [2,5–6].

The host's initial barrier against GAS infection involves the physical integrity of mucosal or skin epithelium and the beneficial antagonism of commensal microflora. However, once GAS has gained a foothold in the host and is poised to breach the epithelial barrier, the innate immune system becomes central in defense against invasive infection. Front line effectors of innate immunity are 'professional' phagocytic cells, including macrophages (M Φ s), dendritic cells (DCs) and monocytes, along with granulocytic cells types such as neutrophils and mast cells. These leukocytes are distinguished from 'nonprofessional' phagocytes by their effectiveness in internalizing large particles, such as cellular debris, apoptotic cells and microbial pathogens, into phagosomes (Figure 1) [7]. The phagocytic process is initiated upon recognition of a particle ligand by cell surface receptors. Such receptor–ligand recognition events launch signaling pathways that induce actin cytoskeleton remodeling and extensions of membrane protrusions to surround the ligand, forming a phagocytic cup and ultimately a phagosome after fusion and fission events with vesicles of the endocytic compartment. The nascent phagosome interacts with different types of endosomes to gradually mature from its 'early' to 'late' forms. Ultimately, phagosome fusion with lysosomal compartments forms the phagolysosome (Figure 1) [8].

M Φ s comprise complex populations of self-renewing tissue-resident cells supplemented by additional numbers derived from circulating monocytes in response to physiological stimuli [9–11]. M Φ s are strategically distributed throughout host tissues where they can encounter, ingest and process microorganisms, dead cells and debris, and generate inflammatory signals that recruit or modulate the activity of additional M Φ s or immune effector cells, including neutrophils. M Φ s are dynamic and heterogeneous, due to diverse mechanisms governing their differentiation, tissue distribution, microenvironment and responsiveness to stimuli [12–14]. Compared to other professional phagocytic cells, M Φ phagosomes acidify strongly and rapidly, inhibiting bacterial growth, while activating resident proteases in an attempt to destroy the entire phagocytic cargo [15]. Efficient phagocytosis and killing of GAS by resident M Φ s follows *in vivo* infection [16]. M Φ depletion by carrageenan treatment or blockade of M Φ s phagocytic functions using gadolinium (III) chloride in mice leads to increased mortality following intravenous GAS challenge, showing their important role in GAS bloodstream clearance [16]. Similarly, mice depleted of M Φ s by clodronate showed increased GAS dissemination from an initial soft tissue focus of infection into blood and internal organs [17].

A large body of literature explores the arsenal of individual GAS virulence factors and their pathogenic mechanisms [2,5]. Yes, despite the prominent role of M Φ s in innate defense against the bacterium, molecular mechanisms of GAS–M Φ interaction remain incompletely understood. This review integrates the latest studies on how GAS and its virulence determinants are recognized by M Φ s, highlighting the particular importance of Toll-like receptor (TLR) and inflammasome pathways. We also examine GAS strategies for survival and replication within M Φ s, and the functional and immune signaling responses of M Φ s to the pathogen encounter.

Macrophage recognition of GAS

Recognition through TLR signaling

Multiple receptors on the phagocyte cell surface function to detect signals not normally present in healthy tissues [18]. These molecules, collectively referred to as pattern recognition receptors (PRRs), sense conserved microbial structures called pathogen-associated molecular patterns (PAMPs), and also recognize endogenous molecules released from injured cells, termed damage-associated molecular patterns (DAMPs). Among PRRs, the TLR family is the earliest and best characterized, and TLRs are expressed on most innate immune cells. To date, ten TLRs have been identified in humans and 13 in mice [19]. TLRs sense invading pathogens both outside the cell and in intracellular

Figure 1. Group A *Streptococcus*-induced phagocytosis and xenophagy in macrophages. The phagocytic process is initiated by the recognition of group A *Streptococcus* (GAS) by macrophage (MΦ) surface pattern recognition receptors. Receptor recognition activates signaling pathways that induce remodeling of the actin cytoskeleton to form a phagosome in a process that involves fusion and fission events with vesicles of the endocytic compartment. The formed phagosome interacts with different types of endosomes and lysosomes, leading to development of phagolysosomes. GAS survival within the MΦ is mediated by streptolysin O-induced pore formation, which prevents acidification of the GAS-containing phagolysosome and allows the delivery of its co-toxin NAD-glycohydrolase (NADase) from the phagosome into the MΦ cytosol, increasing streptolysin O cytotoxicity and promoting GAS replication. Intracellular GAS can then be targeted by the autophagy machinery in a process called xenophagy, and ultimately delivered to the autophagosome, although the GAS-derived specific molecules recognized during xenophagy remain unknown (?). PRRs: Pattern recognition receptors.

compartments, such as endosomes and lysosomes [20]. Subcellular localization of TLRs is important for recognition of specific PAMPs and DAMPs [21]. TLR3, TLR7, TLR8 and TLR9 are localized in the endosomal compartments whereas the remaining TLRs signal from the cell membrane [22]. TLR-mediated signaling pathways are initiated commonly via the adaptor protein MyD88 [23], but may also involve TIR domain-containing adaptor-inducing interferon-β (TRIF) [24] or TIR domain-containing adaptor protein [25,26]. MyD88 mediates activation of the key transcription factor NFκB and subsequent inflammatory cytokine gene expression for all TLRs except for TLR3. TLR3 employs TRIF, which is also used by TLR4 together with MyD88, to trigger activation of IRF3 and NFκB transcription factors and subsequent induction of IFN-β [27]. In addition to TLR-mediated intracellular recognition, pathogen-derivative products can also be detected once internalized into the cell in a MyD88-independent manner by other cytosolic PRRs, such as nucleotide-binding (NOD)-like and oligomerization domain (NLRs

Figure 2. Toll-like receptor-mediated group A *Streptococcus* recognition in macrophages. Macrophages express all Toll-like receptors (TLRs), which are responsible for sensing invading pathogens, including group A *Streptococcus* (GAS), both from the cell surface and in intracellular endosomes and lysosomes. Specific GAS-derived molecules activate the TLR-mediated signaling cascades, which require the adaptor MyD88, although some TLRs such as TLR4 use both MyD88 and TRIF adaptors. MyD88 and TRIF mediate the activation of IRF3 and NFκB transcriptional factors and subsequent induction of IFN-β and proinflammatory cytokines, such as TNF-α and IL-6. TLR2 recognizes GAS lipoteichoic acid and peptidoglycan. TLR4, a receptor for lipopolysaccharide of Gram-negative bacteria, has also been shown to have an effect in the recognition of the GAS pore-forming toxin streptolysin O. TLR9 recognizes unmethylated CpG-rich DNA motifs and plays an important role in host defense against GAS by stimulating the production of reactive oxygen species and nitric oxide (NO). Bacterial 23S RNA, including GAS rRNA, is also recognized by TLR signaling, specifically by murine TLR13. Recognition of GAS RNA by TLR13 is dependent on phagocytosis and endosomal GAS recognition.

receptors) [19,20]. Since MΦs express all TLR signaling pathway components, these cells are critical for recognition of GAS virulence determinants both intra- and extra-cellularly (Figure 2).

MyD88-deficient patients have impaired responses to most TLR ligands and display a narrow but potentially life-threatening predisposition to pyogenic bacterial diseases [28,29]. GAS activation of NFκB and MAPK in macrophages *in vitro* leads to production of proinflammatory cytokines TNFα and IL-6 in a fully MyD88-dependent manner [30]. Concurrently, there is an absolute requirement of MyD88 for upregulation of DC maturation markers, such as CD40, CD80 and CD86, and DC production of proinflammatory cytokines IL-12, IL-6 and TNFα, upon GAS infection [31]. In experimental GAS skin infection in mice [32], MyD88 signaling triggered a rapid innate response operating at two levels: upregulation of inflammatory mediators for neutrophil and MΦ recruitment; and expression of regulatory chemokines, such as CXCL9 and CXCL10, inhibiting recruitment of other immune cell types with potential detrimental effects [32]. TNF-α deficient mice are also highly susceptible to GAS soft tissue infections with

a specific defect in M Φ recruitment [17]. However, GAS recognition by TLR receptors upstream of MyD88 remains a subject of some controversy. In mouse M Φ s infected with GAS *ex vivo*, neither activation of MAPK and NF κ B nor production of MyD88-dependent cytokines required TLR4, TLR9 or TLR2 as corroborated in single and triple TLR2/4/9 deficient cells [30], despite an abundance of peptidoglycan and lipoteichoic acid (LTA) in the GAS cell wall, two well characterized TLR2 ligands (Figure 2) [33]. Moreover, TLR2-deficient mice are not hypersusceptible to GAS systemic infection *in vivo* [17]. These contrasting results might be reconciled in two different ways; from the host side, TLR signaling can be functionally redundant with different TLRs and other PRRs such as scavenger receptors (SR) recognizing the same GAS PAMPs; indeed SR can trigger M Φ MyD88 signaling in M Φ [34]. M protein, the major GAS surface-associated virulence factor, had been proposed in two independent studies using monocytes and M Φ s to be recognized by TLR2 [35] and SR-A [36], respectively. A recent study, however, suggested that M protein alone may not be a true TLR2 agonist, but rather when released may remain bound to other GAS cell wall-derived molecules (e.g., peptidoglycan or LTA) that provoke TLR2-dependent cytokine production in the host [37]. From the pathogen perspective, many GAS virulence factors are multifaceted in nature, and inactivation of any particular virulence determinant may be compensated by another that elicits a similar immune response. Fieber and Kovarik [38] also hypothesized that GAS TLR2 agonists such as LTA and peptidoglycan are masked by its hyaluronic acid capsule, a critical evasion factor present in most GAS strains [39], to be recognized only after phagocytosis and breakdown of capsular integrity. The phagosome-specific configuration of TLR family members may preclude substantial TLR2 responses and allow other TLRs to be triggered by GAS ligands [38]. For example, TLR4 is considered a specific receptor for lipopolysaccharide of Gram-negative bacteria; however, TLR4-deficient murine bone marrow-derived M Φ s (BMDMs) have reduced IL-6 and TNF- α expression after challenge with GAS pore-forming toxin streptolysin O (SLO) (Figure 2) and other cholesterol-dependent bacterial cytolysins [40].

Two independent studies in primary human M Φ s [41] and BMDMs [30] showed that GAS also elicits type I interferon signaling and interferon-driven interferon β (IFN- β) production through signaling from endosomal TLRs, for example, TLR3, TLR7, TLR9. Cell surface-localized TLR2 and TLR4 can also become IFN- β inducers after ligand-triggered internalization of the receptors [42,43]. IFN signaling is key to host defense against GAS, and mice lacking type I interferon receptor (IFNAR-1) are hyper-susceptible to lethal invasive GAS infection [44]. BMDM IFN- β production is independent of GAS cytolysins SLO and SLS [30], in contrast to M Φ responses to other Gram-positive pathogens, where cytolysin-mediated escape from phagocytic vesicles is implicated in interferon induction [40,45–47]. GAS-derived DNA is the PAMP inducing IFN- β in BMDMs, involving both MyD88-dependent and -independent pathways, with full IRF3 control in the absence of known IFN- β -inducing PRRs NOD1, NOD2, TLR3, TLR7 and TLR9 [44]. TLR9 recognizes unmethylated CpG-rich DNA motifs and plays important role in host defense against GAS, improving M Φ killing of the pathogen by inducing transcription factor HIF-1 α and increasing bactericidal reactive oxygen species and nitrogen oxide (NO) generation (Figure 2) [48]. However, in invasive M1 GAS strains, the potent secreted DNase Sda1 [49] can degrade the bacterium's own CpG-rich DNA to block TLR9-mediated IFN- α and TNF- α production, blunting bactericidal activity [50]. GAS 23S rRNA is also recognized by TLR13 [51–53] following phagocytosis in murine M Φ s (Figure 2) [54]. However, while expressed in all kingdoms, only a few mammals possess TLR13, with humans lacking the receptor. Instead, GAS 23S rRNA is detected by TLR8 in human monocyte-derived M Φ s [55]. In summary, recognition of GAS nucleic acids is an important alarm likely to play a significant role in immune susceptibility to the pathogen.

Inflammasome recognition & IL-1 β signaling

Inflammasomes are macromolecular protein assemblies that impact inflammatory responses to environmental stimuli and serve a key function in innate defense against diverse pathogens [56]. Dysregulated inflammasome activation, however, can predispose the host to chronic autoimmune and inflammatory pathologies, cancer or neurodegenerative diseases. Thus, inflammasome assembly and downstream signaling must be finely tuned to simultaneously promote rapid antimicrobial or inflammatory responses while limiting unwanted tissue injury [57].

Five sensor proteins have been proven to assemble inflammasomes in response to PAMPs and/or DAMPs, including the nucleotide-binding oligomerization domain (NOD), leucine-rich repeat containing receptor (NLR) family members NLRP1, NLRP3 and NLRC4 and the proteins absent in melanoma-2 (AIM2) and pyrin. Recognition of the correct inflammatory stimulus leads to sensor activation, oligomerization and recruitment of the adaptor protein ASC, and activation of cysteine protease caspase-1, leading to proteolytic processing of inactive pro-IL-1 β and pro-IL-18 into their mature forms, IL-1 β and IL-18—all hallmarks of inflammasome activation [58,59].

IL-1 β signaling is critical for defense against several streptococcal species [60], including GAS [61,62]. Knockout mice lacking the IL-1 receptor (IL-1R) and therefore unresponsive to IL-1 β signaling are more susceptible to GAS infections, in part due to the contribution of IL-1 β to neutrophil influx at the site of infection [61]. US FDA-approved IL-1 β inhibitor Anakinra reduces M Φ killing of GAS [63] and facilitates GAS replication and dissemination in infected mice [62,63].

Most of the known inflammasomes respond to specific microbial stimuli. Lethal toxin of *Bacillus anthracis* and *Toxoplasma gondii* infection activates NLRP1 [64–66], AIM2 recognizes double-stranded DNA from lysed intracellular bacteria [67,68], NLRC4 responds to bacterial flagellin and type 3 secretion systems [69,70] while pyrin senses Rho GTPase modifications induced by bacterial toxins [71]. A role of these inflammasomes in GAS recognition has yet to be described. In contrast, the NLRP3 inflammasome responds to a surprisingly diverse set of PAMPs and DAMPs [72], and is a relevant contributor to M Φ detection of GAS; IL-1 β production is impaired in NLRP3 [–/–] deficient mice infected with the pathogen [73].

Two GAS proteins were initially described to be detected by the canonical NLRP3 inflammasome, the pore-forming toxin SLO [73] and the ADP-ribosyltransferase SpyA toxin (Figure 3) [62]. In addition to activation of IL-1 β signaling, these two GAS virulence factors induce a rapid, necrotic and inflammatory programmed cell death termed ‘pyroptosis’ [74]. Bacterial pore-forming toxins are often detected by the NLRP3 inflammasome complex [75], and SLO promotes immune evasion by accelerating cell death [76,77]. SLO is released as a monomer that binds cholesterol in cell membranes and oligomerizes to form large transmembrane pores [78] while concurrently activating IL-1 β and pyroptosis through NLRP3 [73,79]. Activation of the NLRP3 inflammasome depends on two signals: a priming signal for upregulation of NLRP3 and pro-IL-1 β , and a second signal that triggers assembly of the inflammasome complex (Figure 3) [80,81]. Consistent with this feature, co-stimulation of M Φ s with recombinant SLO and certain TLR ligands, but not each stimulus alone, triggered caspase-1 activation through the NLRP3 inflammasome [82]. M Φ cell death ultimately provoked by SLO reduces IL-1 β secretion, [76] and experiments in which M Φ s were treated with modified SLO derivative that produce strands and altered pores could yield a more robust adjuvant effect through enhanced IL-1 β secretion [79]. The precise mechanism of SLO detection by NLRP3 is not clear, although NLRP3 does not appear to directly sense GAS pore-forming toxins by direct binding [60]. Similar to other bacterial pore-forming toxins, SLO can activate other M Φ cell death pathways that have features of osmotic lysis, apoptosis and oncosis [76,83]. However, since pyroptosis occurs more rapidly, it may predominate over other cell death processes during many GAS–M Φ encounters in conjunction with SLO-mediated IL-1 β signaling.

The NLRP3 inflammasome is activated by SpyA, a membrane-bound C3-like ADP-ribosyltransferase that contributes to GAS pathogenesis in mouse cutaneous infection models [84–86]. However, in systemic infection, SpyA-deficient GAS evade M Φ killing and cause higher mortality and bacterial burdens, suggesting that recognition of SpyA is important for host defense against GAS [62]. Anakinra treatment exaggerates these SpyA-dependent virulence phenotypes, highlighting the importance of IL-1 β signaling for limiting GAS replication. SpyA triggers M Φ cell death along with NLRP3 and caspase-1 dependent IL-1 β secretion, similarly to other ADP-ribosylating toxins from *Pseudomonas aeruginosa* [62] and *Mycoplasma pneumonia* [87]. However, the putative PRRs involved in the recognition of SpyA and its homologs upstream of NLRP3 activation still require elucidation. A single common receptor for this family of bacterial toxins is unlikely, however, since an ADP-ribosyltransferase toxin from *Clostridium botulinum* activates IL-1 β signaling via the pyrin inflammasome [71].

In addition to caspase-1 activation and pyroptosis, SLO and SpyA also activate caspase-3 in M Φ [62,76], a phenomenon traditionally linked to apoptosis. Pyroptosis induction was recently shown to require gasdermin D (GSDMD), a member of the enigmatic gasdermin protein family [88–90]. GSDMD is cleaved by inflammatory caspases, resulting in the generation of an N-terminal fragment that leads to pyroptotic cell death. However, recent studies have shown that in the absence of GSDMD, caspase-1 activates caspase-3 and -7 to induce apoptosis. Conversely, during apoptosis, caspase-3/-7 specifically blocks pyroptosis by cleaving GSDMD at a distinct site from the inflammatory caspase-1, resulting in its inactivation and revealing a bidirectional crosstalk between apoptosis and pyroptosis in monocytes and M Φ s [91].

In very recent work from our laboratory [37], we found that M protein, the most abundant protein on the GAS surface [92] and one of the best studied of all Gram-positive bacterial virulence factors [93], makes an independent and important contribution to activation of the NLRP3 inflammasome. GAS strains are immunologically classified into >220 serotypes based on M protein variation [94]. However, only a limited number of M protein/*emm* types are widespread and associated with severe invasive infections, with serotype M1/*emm1* being the most prevalent cause of severe invasive GAS infections in recent decades [95–97]. M proteins can be released during infection by the

Figure 3. Comparison between group A *Streptococcus*-induced noncanonical and NLRP3 canonical IL-1 β signaling activation. During early stages of group A *Streptococcus* (GAS) infection, the proteolytic activity of the GAS cysteine protease SpeB hastens degradation of all known GAS canonical NLRP3 activators: streptolysin O (SLO), SpyA and M protein. SpeB also elicits the maturation of the proinflammatory cytokine pro-IL-1 β by direct cleavage to its mature form IL-1 β , overriding the contribution of the NLRP3 inflammasome. During the progress from mild to severe invasive GAS infections, mutations of *covR/S* take place, inactivating SpeB, while accelerating the expression and release of SLO, SpyA and M protein. Canonical NLRP3 inflammasome activation depends on two signals. Pathogen-associated molecular patterns are recognized by specific pattern recognition receptors, to induce the transcriptional activation of *il-1 β* and other inflammasome components (signal 1). SLO pore formation, uptake of soluble M protein by clathrin-mediated endocytosis (CME) and SpyA make an independent contribution to the activation and assembly of the NLRP3 inflammasome and trigger potassium efflux (K $^{+}$) efflux through an unknown mechanism (?). The assembly of the inflammasome leads to the caspase-1-dependent processing of pro-IL-1 β to IL-1 β , and resulting in DNA damage and pyroptotic cell death in macrophages. PAMPs: Pathogen-associated molecular patterns; PRRs: Pattern recognition receptors.

action of neutrophil-derived granule proteases and exert proinflammatory effects through their interaction with host factors [98,99]. Released M1 protein and of itself triggers tissue injury and vascular leakage *in vivo*, similar to that observed in severe GAS NF and streptococcal toxic-shock syndrome [98,100–101]. Under physiological conditions, M1 protein is also released from the GAS surface and detected extracellularly in high concentrations [102]. M1, through its structurally dynamic B-repeat domain, serves as a second signal for caspase-1-dependent NLRP3 inflammasome activation, IL-1 β maturation and M Φ pyroptosis. M1-induced M Φ IL-1 β signaling involves K $^{+}$ efflux, a common step in NLRP3 inflammasome activation [103], and M1 internalization by clathrin-mediated endocytosis (Figure 3) [37]. GAS-infected mice produced more IL-1 β *in vivo* than GAS lacking M1-infected mice. Indeed, soluble M1 was itself sufficient and specific for IL-1 β activation *in vitro* and *in vivo* [37]. GAS-mediated canonical NLRP3 and IL-1 β activation through the independent contributions of M1, SLO and SpyA exemplifies the complexity of GAS virulence factors and how the host applies a multifaceted approach to pathogen detection.

In a discovery that changed conventional dogma regarding IL-1 β signaling in innate immunity, GAS was found to be capable of noncanonical, inflammasome-independent IL-1 β activation, via direct cleavage of pro-IL-1 β by its

broad-spectrum cysteine protease, SpeB. The most abundant secreted protein in GAS culture supernatants, SpeB also cleaves several GAS surface-associated and secreted virulence factors (Figure 3) [104,105]. In this fashion, IL-1 β itself acts as a sensor to directly respond to pathogen-associated proteolysis through an independent pathway operating in parallel to inflammasomes [63]. Both canonical NLRP3 inflammasome and noncanonical IL-1 β signaling occur in M Φ s responding to a GAS encounter, and likely depend on the site, stage and magnitude of infection, from initial colonization to systemic disease. Of note, SpeB itself degrades the canonical inflammasome-activating GAS virulence factors SLO, SpyA and M protein [63,104,106], suggesting that noncanonical IL-1 β signaling may predominate whenever SpeB expression is activated. However, in M1T1 GAS and certain other invasive serotypes, naturally occurring mutations in the two-component regulatory system CovR/CovS (encoded by *covRS* genes) can arise *in vivo*, leading to upregulation of several virulence factors, such as, SLO and SpyA, while suppressing expression of SpeB. Absence of SpeB spares the GAS canonical NLRP3 activators from proteolytic degradation and increases the levels of their soluble forms [5,104,107–108]. Epidemiological studies have found that SpeB expression and activity are significantly higher in GAS serotype M1T1 isolates from nonsevere invasive infections than isolates from severe cases [106,109–110]. Based on this evidence, we propose a model (Figure 3) wherein during early stages of GAS infection, all known GAS canonical NLRP3 activators are partially degraded by active SpeB proteolysis, which also directly processes pro-IL-1 β to the active cytokine, providing an early signal to activate host immunity against the pathogen. During the progression of GAS infection *in vivo*, mutations of *covR/S* take place, silencing SpeB expression and eliminating the noncanonical IL-1 β signaling response that helps guard against invasive infection. As the organism gains a foothold deep in the body or the bloodstream, expression and release of SLO, SpyA and M protein are upregulated and these factors are no longer degraded by SpeB. In later stages of infection, canonical NLRP3 inflammasome activation in response to these virulence determinants may be associated with hyperinflammation, aggravating tissue injury and toxic-shock syndrome.

Survival & replication of GAS in macrophages

Although GAS has traditionally been considered an extracellular pathogen, it can invade host cells and persist in an intracellular environment [111]. Intracellular reservoirs of viable GAS have been identified in different cell types, including epithelial cells [112,113], neutrophils [114] and M Φ s [115–117]. GAS intracellular survival may promote persistent colonization and dissemination by shielding the bacterium from immune effectors and antibiotics. For many intracellular pathogens, survival within M Φ s may be achieved by transitioning the host cell to an anti-inflammatory, immunomodulatory ('alternatively activated') M2 phenotype, in contrast to the proinflammatory, microbicidal ('classically activated') M1 phenotype commonly associated with infection [118]. In this context, human and murine M Φ s differ in their responses to GAS. In humans, GAS induces a M1 profile characterized by enhanced mRNA expression of inflammatory chemokines, such as, CCL2, CCL5, CXCL8 and CXCL10 [119], whereas in mice, the pathogen stimulates an unusual activation program that combines M1 and M2 profiles [120]. The two M Φ phenotypes are defined by their cytokine/chemokine receptor profiles, and NF κ B signaling drives their polarization [121]. Viable GAS has been recovered from biopsies of patients with soft tissue infections, and bacteria are present both extracellularly and intracellularly within phagocytic cells, primarily within M Φ s [117]. In these studies, intracellular GAS was predominantly found in biopsies characterized by lower inflammation and bacterial load, whereas purely extracellular GAS or a combination of intra- and extra-cellular GAS dominated in severely inflamed tissue despite intravenous antibiotic therapy, suggesting that internalization can promote the spread of GAS within the tissue [117]. Different intracellular survival strategies of the pathogen have been proposed, including SLO-dependent evasion of lysosomal killing in epithelial cells [122] and GAS M1 protein-mediated inhibition of granule fusion with the phagosomes of neutrophils [123]. Internalization of GAS in host cells could provide a safe haven from immune cell and antibiotic-mediated killing *in vivo* [112,124]. In primary human monocyte-derived M Φ s, GAS resides within spacious phagocytic vacuoles surrounded by an electron-dense membrane, and intracellular bacteria remain within these vacuoles up to 12 h [116]. An initial study showed *in vitro* evidence of a relationship between GAS survival and M1 protein-dependent intracellular trafficking in the phagosomal–lysosomal pathway, which resulted in impaired fusion with lysosomes [116]. However, another study found the partnership between SLO and its intimately associated co-toxin NAD-glycohydrolase (NADase) to drive GAS intracellular survival during infection in M Φ s by two mechanisms [115]. SLO-induced pore formation prevents acidification of the GAS-containing phagolysosome, thereby impairing effective bacterial killing. SLO-mediated translocation delivers NADase from the phagosome into the M Φ cytosol, where NADase compounds SLO cytotoxicity by inhibiting cellular repair mechanisms (Figure 1) [115]. In epithelial cells by contrast, both toxins inhibit transport of the GAS-

containing vacuole to a functional bactericidal compartment by inhibiting fusion with lysosomes [122,125–126]. GAS resistance to phagocytosis and escape from the phagolysosome machinery may be exaggerated in invasive infections, when *covRS* spontaneous mutations markedly upregulate both SLO and NADase [127–129]. Single cell and time-lapse microscopy analysis demonstrated that GAS not only survived in MΦs, but replicated intracellularly to form strikingly long chains (Figure 1) [130], reminiscent of chain elongation seen in response to other environmental stresses such as reduced pH and nutrient limitation. SLO expression, but not M protein, is also required for replication of GAS within the MΦ [130]. SLO-dependent phagosomal rupture leads to a significant proportion of cytosolic GAS. These recent findings support the idea that the intracellular compartment is a place of silent sequestration for the pathogen [111].

Autophagy is an intracellular degradation system that delivers cytoplasmic constituents to the lysosome and is mediated by a unique organelle, the autophagosome [131–134]. Distinct from endocytosis-mediated lysosomal degradation [133], the autophagic response against intracellular pathogens is named xenophagy, involving selective uptake of invading microorganisms via signals, autophagic adaptors and receptors, and delivery of the cargo to autophagosomes [135,136]. In autophagy-deficient cells, GAS shows enhanced survival and proliferation [137,138], whereas in cells with enhanced baseline autophagy, GAS is more rapidly cleared [139]. After escaping from endosomes into the cytoplasm, GAS is targeted for autophagic degradation via ubiquitination and LC3 labeling, a critical marker in the autophagy pathway, resulting in the formation of GAS-containing, autophagosome-like vacuoles (GcAVs), wherein the pathogen is subsequently killed upon fusion of these compartments with lysosomes (Figure 1) [138]. GAS can also directly induce autophagy upon recognition by the cell surface receptor CD46, without any further delay [137]. Host small G proteins, including Rab5 and Rab7, are associated with autophagosome formation and the fate of intracellular GAS. Rab5 is involved in bacterial invasion and endosome fusion, while Rab7 is multifunctional, contributing to bacterial invasion, endosome maturation and autophagosome formation [140,141]. Other small GTPases, such as Rab9A and Rab23, also play roles in xenophagic clearance of GAS [142].

Successful activation of the autophagic machinery and elimination of GAS by the cell depends on the GAS strain and its repertoire of virulence determinants. Certain strains from serotypes not commonly associated with human invasive disease epidemiology, including M6 [137–138,140], M49 [137] and M89 [143] are efficiently targeted to autophagy and cleared, whereas globally disseminated M1T1 clone of GAS replicates efficiently in the cytosol of infected epithelial cells. M1T1 GAS evades autophagy through SpeB-mediated degradation of the ubiquitin-autophagy adaptor proteins p62, NDP52 and NBR1 [144]. However, the phenomenon wherein SpeB impairs GAS-induced autophagy in epithelial cells is less prominent in MΦs, since both M1T1 5448 and M49 NZ131 GAS strains, which harbor active SpeB, are recognized by ubiquitin and p62 and associated with LC3 [130]. Not all cytosolic bacteria are targeted to the xenophagy pathway in MΦs, indicating a subpopulation of cytosolic GAS that is not recognized or evades autophagy-mediated growth attenuation following GcAV rupture [130]. The molecular basis for replication of GAS within the MΦ cytosol, and whether specific bacterial virulence determinants are targeting the autophagic machinery of these professional phagocytic cells, still need to be elucidated (Figure 1). Future comparisons of the stage and efficiency of the phagosomal–lysosomal versus autophagy pathways will lead to a better understanding of the intracellular GAS fate, and perhaps identify additional autophagic adaptors and regulatory mechanisms that specifically target, attack and degrade the pathogen. In this sense, autophagy and phagocytosis may overlap mechanistically. In *Mycobacterium*, activation of TLR signaling enhances phagosome maturation and at the same time, increases recruitment of the bacteria into autophagosomes [145]. Accordingly, LC3, the critical component in the autophagy pathway, can be recruited to phagosomes following the exposure of MΦs to TLR agonist-coated beads or zymosan [146]. New evidence highlights an interaction between autophagy and phagocytosis, as autophagy-deficient MΦs have increased levels of class A scavenger receptors, leading to higher phagocytic uptake [147].

Conclusion & future perspective

MΦs are essential in the host response to GAS, not just as professional detectors of the bacteria, resulting in the release of inflammatory alarms, but also as direct killers through phagocytosis and xenophagy. However, survival and replication versus recognition, inflammatory response and killing mechanisms, cannot be considered as single events, since many of them overlap and are dependent on each other. This review has highlighted events that occur during the different stages of GAS–MΦ interaction, and the various virulence strategies that GAS deploys to coordinate its escape from phagocytic cell clearance. Further efforts to identify in more detail the specific interactions

and the integration of both bacteria and cell strategies for survival may allow the development of new virulence inhibitors or host-directed therapeutic options against this important human pathogen.

Executive summary

Group A *Streptococcus* in human infection

- Group A *Streptococcus* (GAS) is a leading human pathogen on a global scale, responsible for several diseases ranging from mild to severe infections, and potential immune sequelae after repeated GAS exposures.
- Nearly 2 million new cases of serious GAS disease occur each year, accounting for 517,000 deaths annually, placing GAS among the top 10 causes of human infectious disease mortality.
- GAS is protected by a multitude of surface-bound and secreted virulence factors that are variably expressed among GAS strains and from different host susceptibilities.

Macrophages (MΦs) play a critical role during GAS infections

- MΦs are strategically located throughout the body tissues where they ingest and process microorganisms.
- MΦs are highly effective at phagocytosis because of the strong and rapid acidification of their phagosomes, activating proteases and peptides that inhibit bacteria growth or destroy the entire phagocytic cargo.
- Efficient MΦ phagocytosis and killing of GAS has been demonstrated *in vitro*, and resident MΦs aid in GAS clearance during *in vivo* infection.
- Depletion of MΦs or inhibition of their phagocytic properties leads to a substantial increase in GAS dissemination from tissues into blood and internal organs, supporting the key role of this immune cell type in the control of GAS virulence.

Toll-like receptors mediated MΦ recognition of GAS

- MΦ express a multitude of pattern recognition receptors to detect signals that are not normally found in healthy tissues.
- Toll-like receptor (TLR) family is the best characterized of pattern recognition receptors and is responsible for sensing GAS outside of the cell and in intracellular endosomes and lysosomes.
- GAS-induced TLR signaling pathways result in the production of inflammatory cytokines and IFN- β , in a manner completely dependent on adaptor MyD88.
- Although the upstream recognition of GAS by TLRs is incompletely understood, different GAS molecules have been reported to be recognized by specific TLRs.

Inflammasome-mediated recognition of GAS & IL-1 β signaling

- Inflammasomes are key elements of innate immunity recognized to control the inflammatory response to various stimuli and for their crucial role in host defense against pathogens.
- Activation of IL-1 β signaling is critical in defense against several streptococcal species, including GAS.
- NLRP3 inflammasomes respond to a surprisingly diverse set of pathogen-associated molecular patterns and damage-associated molecular patterns, and make a significant contribution to MΦs detection of GAS.
- Three GAS virulence factors – pore-forming toxin streptolysin O (SLO), ADP-ribosyltransferase SpyA and M protein – are detected by NLRP3, each making an independent contribution to IL-1 β signaling.
- As a consequence of canonical NLRP3 activation, SLO, SpyA and M protein induce pyroptotic cell death in macrophages.
- GAS also induces noncanonical IL-1 β activation via direct cleavage of the cytokine precursor by SpeB, a broad-spectrum, GAS-secreted protease.

Survival & replication of GAS in macrophages

- Although traditionally considered an extracellular pathogen, GAS invades host cells and persists in their intracellular environment.
- GAS intracellular survival may promote persistence, pathogen colonization and dissemination of the infection *in vivo*.
- Once inside the MΦs, GAS resides within spacious phagocytic vacuoles surrounded by an electron-dense membrane; intracellular GAS remains within these vacuoles up to 12 h.
- SLO and its intimately associated co-toxin NAD-glycohydrolase (NADase) are a key GAS virulence mechanism driving GAS intracellular survival and resistance to MΦ killing.
- Surviving intracellular GAS can replicate and even form long chains within human MΦs.
- GAS replication occurs in the macrophage cytosol after SLO-dependent phagosomal rupture, leading to a significant proportion of cytosolic bacteria.
- After escaping from endosomes into the cytoplasm, GAS is targeted by the autophagy machinery (xenophagy), which can deliver bacteria to be eliminated in autophagosomes.

Financial & competing interests disclosure

This work was supported by National Institutes of Health grants number AI077780 and AI096837. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest

1. Carapetis JR, Beaton A, Cunningham MW *et al.* Acute rheumatic fever and rheumatic heart disease. *Nat. Rev. Dis. Primers* 2, 15084 (2016).
2. Walker MJ, Barnett TC, McArthur JD *et al.* Disease manifestations and pathogenic mechanisms of group A *Streptococcus*. *Clin. Microbiol. Rev.* 27, 264–301 (2014).
3. Ralph AP, Carapetis JR. Group A streptococcal diseases and their global burden. *Curr. Top. Microbiol. Immunol.* 368, 1–27 (2013).
4. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. *Lancet Infect. Dis.* 5, 685–694 (2005).
5. Cole JN, Barnett TC, Nizet V, Walker MJ. Molecular insight into invasive group A streptococcal disease. *Nat. Rev. Microbiol.* 9, 724–736 (2011).
6. Lynskey NN, Lawrenson RA, Sriskandan S. New understandings in *Streptococcus pyogenes*. *Curr. Opin. Infect. Dis.* 24, 196–202 (2011).
7. Sarantis H, Grinstein S. Subversion of phagocytosis for pathogen survival. *Cell Host Microbe* 12, 419–431 (2012).
8. Pauwels AM, Trost M, Beyaert R, Hoffmann E. Patterns, receptors, and signals: regulation of phagosome maturation. *Trends Immunol.* 38, 407–422 (2017).
9. Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. *Nat. Immunol.* 7, 311–317 (2006).
10. Gomez Perdiguero E, Klapproth K, Schulz C *et al.* Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. *Nature* 518, 547–551 (2015).
11. Hoeffel G, Chen J, Lavin Y *et al.* C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. *Immunity* 42, 665–678 (2015).
12. Gordon S. Alternative activation of macrophages. *Nat. Rev. Immunol.* 3, 23–35 (2003).
13. Mosser DM. The many faces of macrophage activation. *J. Leukoc. Biol.* 73, 209–212 (2003).
14. Strauss-Ayali D, Conrad SM, Mosser DM. Monocyte subpopulations and their differentiation patterns during infection. *J. Leukoc. Biol.* 82, 244–252 (2007).
15. Yates RM, Hermetter A, Russell DG. The kinetics of phagosome maturation as a function of phagosome/lysosome fusion and acquisition of hydrolytic activity. *Traffic* 6, 413–420 (2005).
16. Goldmann O, Rohde M, Chhatwal GS, Medina E. Role of macrophages in host resistance to group A streptococci. *Infect. Immun.* 72, 2956–2963 (2004).
17. Mishalian I, Ordan M, Peled A *et al.* Recruited macrophages control dissemination of group A *Streptococcus* from infected soft tissues. *J. Immunol.* 187, 6022–6031 (2011).
18. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. *Nat. Rev. Immunol.* 11, 723–737 (2011).
19. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. *Cell* 140, 805–820 (2010).
20. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell* 124, 783–801 (2006).
21. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. *Nat. Rev. Immunol.* 9, 535–542 (2009).
22. McGettrick AF, O'Neill LA. Localisation and trafficking of Toll-like receptors: an important mode of regulation. *Curr. Opin. Immunol.* 22, 20–27 (2010).
23. Medzhitov R, Preston-Hurlburt P, Kopp E *et al.* MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. *Mol. Cell* 2, 253–258 (1998).
24. Yamamoto M, Sato S, Hemmi H *et al.* Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. *Science* 301, 640–643 (2003).
25. Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. *Nat. Immunol.* 2, 835–841 (2001).
26. Yamamoto M, Sato S, Hemmi H *et al.* Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. *Nature* 420, 324–329 (2002).
27. Takeda K, Akira S. Toll-like receptors. *Curr. Protoc. Immunol.* 109, 11–10 (2015).

28. von Bernuth H, Picard C, Jin Z *et al.* Pyogenic bacterial infections in humans with MyD88 deficiency. *Science* 321, 691–696 (2008).
29. Picard C, Puel A, Bonnet M *et al.* Pyogenic bacterial infections in humans with IRAK-4 deficiency. *Science* 299, 2076–2079 (2003).
30. Gratz N, Siller M, Schaljo B *et al.* Group A *Streptococcus* activates type I interferon production and MyD88-dependent signaling without involvement of TLR2, TLR4, and TLR9. *J. Biol. Chem.* 283, 19879–19887 (2008).
31. Loof TG, Goldmann O, Medina E. Immune recognition of *Streptococcus pyogenes* by dendritic cells. *Infect. Immun.* 76, 2785–2792 (2008).
32. Loof TG, Goldmann O, Gessner A, Herwald H, Medina E. Aberrant inflammatory response to *Streptococcus pyogenes* in mice lacking myeloid differentiation factor 88. *Am. J. Pathol.* 176, 754–763 (2010).
33. Oliveira-Nascimento L, Massari P, Wetzler LM. The role of TLR2 in infection and immunity. *Front. Immunol.* 3, 79 (2012).
34. Geiger-Maor A, Levi I, Even-Ram S *et al.* Cells exposed to sublethal oxidative stress selectively attract monocytes/macrophages via scavenger receptors and MyD88-mediated signaling. *J. Immunol.* 188, 1234–1244 (2012).
35. Pahlman LI, Mörgelin M, Eckert J *et al.* Streptococcal M protein: a multipotent and powerful inducer of inflammation. *J. Immunol.* 177, 1221–1228 (2006).
36. Areschoug T, Waldemarsson J, Gordon S. Evasion of macrophage scavenger receptor A-mediated recognition by pathogenic streptococci. *Eur. J. Immunol.* 38, 3068–3079 (2008).
37. Valderrama JA, Riestra AM, Gao NJ *et al.* Group A streptococcal M protein activates the NLRP3 inflammasome. *Nat. Microbiol.* 2, 1425–1434 (2017).
- **When released from the bacterial surface, the classical Group A *Streptococcus* (GAS) virulence factor triggers rapid macrophage cell death by pyroptosis accompanied by proinflammatory IL-1 β signaling.**
38. Fieber C, Kovarik P. Responses of innate immune cells to group A *Streptococcus*. *Front. Cell Infect. Microbiol.* 4, 140 (2014).
39. Stollerman GH, Dale JB. The importance of the group A *Streptococcus* capsule in the pathogenesis of human infections: a historical perspective. *Clin. Infect. Dis.* 46, 1038–1045 (2008).
40. Park JM, Ng VH, Maeda S, Rest RF, Karin M. Anthrolysin O and other Gram-positive cytolysins are Toll-like receptor 4 agonists. *J. Exp. Med.* 200, 1647–1655 (2004).
41. Miettinen M, Lehtonen A, Julkunen I, Matikainen S. Lactobacilli and streptococci activate NF κ B and STAT signaling pathways in human macrophages. *J. Immunol.* 164, 3733–3740 (2000).
42. Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. *Nat. Immunol.* 10, 1200–1207 (2009).
43. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. *Nat. Immunol.* 9, 361–368 (2008).
44. Gratz N, Hartweg H, Matt U *et al.* Type I interferon production induced by *Streptococcus pyogenes*-derived nucleic acids is required for host protection. *PLoS Pathog.* 7, e1001345 (2011).
45. Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. *Immunity* 24, 93–103 (2006).
46. O’Riordan M, Yi CH, Gonzales R, Lee KD, Portnoy DA. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. *Proc. Natl Acad. Sci. USA* 99, 13861–13866 (2002).
47. Stockinger S, Materna T, Stoiber D *et al.* Production of type I IFN sensitizes macrophages to cell death induced by *Listeria monocytogenes*. *J. Immunol.* 169, 6522–6529 (2002).
48. Zinkernagel AS, Hruz P, Uchiyama S *et al.* Importance of Toll-like receptor 9 in host defense against M1T1 Group A *Streptococcus* infections. *J. Innate Immun.* 4, 213–218 (2012).
49. Aziz RK, Ismail SA, Park HW, Korb M. Post-proteomic identification of a novel phage-encoded streptodornase, Sda1, in invasive M1T1 *Streptococcus pyogenes*. *Mol. Microbiol.* 54, 184–197 (2004).
50. Uchiyama S, Andreoni F, Schuepbach RA, Nizet V, Zinkernagel AS. DNase Sda1 allows invasive M1T1 group A *Streptococcus* to prevent TLR9-dependent recognition. *PLoS Pathog.* 8, e1002736 (2012).
51. Oldenburg M, Krüger A, Ferstl R *et al.* TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. *Science* 337, 1111–1115 (2012).
52. Li XD, Chen ZJ. Sequence specific detection of bacterial 23S ribosomal RNA by TLR13. *Elife* 1, e00102 (2012).
53. Hidmark A, von Saint Paul A, Dalpke AH. Cutting edge: TLR13 is a receptor for bacterial RNA. *J. Immunol.* 189, 2717–2721 (2012).
54. Fieber C, Janos M, Koestler T *et al.* Innate immune response to *Streptococcus pyogenes* depends on the combined activation of TLR13 and TLR2. *PLoS ONE* 10, e0119727 (2015).
55. Eigenbrod T, Pelka K, Latz E, Kreikemeyer B, Dalpke AH. TLR8 senses bacterial RNA in human monocytes and plays a nonredundant role for recognition of *Streptococcus pyogenes*. *J. Immunol.* 195, 1092–1099 (2015).

56. von Moltke J, Ayres JS, Kofoed EM, Chavarria-Smith J, Vance RE. Recognition of bacteria by inflammasomes. *Annu. Rev. Immunol.* 31, 73–106 (2013).
57. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. *Nat. Rev. Immunol.* 16, 407–420 (2016).
58. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. *Mol. Cell* 10, 417–426 (2002).
59. Man SM, Karki R, Kanneganti TD. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. *Immunol. Rev.* 277, 61–75 (2017).
60. LaRock CN, Nizet V. Inflammasome/IL-1 β responses to streptococcal pathogens. *Front. Immunol.* 6, 518 (2015).
61. Hsu LC, Enzler T, Seita J *et al.* IL-1 β -driven neutrophilia preserves antibacterial defense in the absence of the kinase IKK β . *Nat. Immunol.* 12, 144–150 (2011).
62. Lin AE, Beasley FC, Keller N *et al.* A group A *Streptococcus* ADP-ribosyltransferase toxin stimulates a protective interleukin 1 β -dependent macrophage immune response. *MBio* 6, e00133 (2015).
63. LaRock CN, Todd J, LaRock DL *et al.* IL-1 β is an innate immune sensor of microbial proteolysis. *Sci. Immunol.* 1, eaah3539 (2016).
- **Studies with GAS reveal inflammasome-independent IL-1 β signaling to a bacterial pathogen – perhaps the simplest innate immune response known, where one protein is both the sensor and effector of macrophage-mediated defense.**
64. Boyden ED, Dietrich WF. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. *Nat. Genet.* 38, 240–244 (2006).
65. Ewald SE, Chavarria-Smith J, Boothroyd JC. NLRP1 is an inflammasome sensor for *Toxoplasma gondii*. *Infect. Immun.* 82, 460–468 (2014).
66. Levinsohn JL, Newman ZL, Hellmich KA *et al.* Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. *PLoS Pathog.* 8, e1002638 (2012).
67. Jones JW, Kayagaki N, Broz P *et al.* Absent in melanoma 2 is required for innate immune recognition of *Francisella tularensis*. *Proc. Natl Acad. Sci. USA* 107, 9771–9776 (2010).
68. Sauer JD, Witte CE, Zemansky J, Hanson B, Lauer P, Portnoy DA. *Listeria monocytogenes* triggers AIM2-mediated pyroptosis upon infrequent bacteriolysis in the macrophage cytosol. *Cell Host Microbe* 7, 412–419 (2010).
69. Zhao Y, Yang J, Shi J *et al.* The NLRP4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. *Nature* 477, 596–600 (2011).
70. Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. *Nature* 477, 592–595 (2011).
71. Xu H, Yang J, Gao W *et al.* Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. *Nature* 513, 237–241 (2014).
72. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. *Nat. Rev. Immunol.* 13, 397–411 (2013).
73. Harder J, Franchi L, Muñoz-Planillo R, Park JH, Reimer T, Núñez G. Activation of the Nlrp3 inflammasome by *Streptococcus pyogenes* requires streptolysin O and NF- κ B activation but proceeds independently of TLR signaling and P2X7 receptor. *J. Immunol.* 183, 5823–5829 (2009).
74. Vande Walle L, Lamkanfi M. Pyroptosis. *Curr. Biol.* 26, R568–R572 (2016).
75. Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. *Cell. Mol. Immunol.* 13, 148–159 (2016).
76. Timmer AM, Timmer JC, Pence MA *et al.* Streptolysin O promotes group A *Streptococcus* immune evasion by accelerated macrophage apoptosis. *J. Biol. Chem.* 284, 862–871 (2009).
77. Sierig G, Cywes C, Wessels MR, Ashbaugh CD. Cytotoxic effects of streptolysin O and streptolysin S enhance the virulence of poorly encapsulated Group A Streptococci. *Infect. Immun.* 71, 446–455 (2003).
78. Feil SC, Ascher DB, Kuiper MJ, Tweten RK, Parker MW. Structural studies of *Streptococcus pyogenes* streptolysin O provide insights into the early steps of membrane penetration. *J. Mol. Biol.* 426, 785–792 (2014).
79. Keyel PA, Roth R, Yokoyama WM, Heuser JE, Salter RD. Reduction of streptolysin O (SLO) pore-forming activity enhances inflammasome activation. *Toxins (Basel)* 5, 1105–1118 (2013).
80. Broz P. Inflammasomes: intracellular detection of extracellular bacteria. *Cell Res.* 26, 859–860 (2016).
81. Vanaja SK, Rathinam VA, Fitzgerald KA. Mechanisms of inflammasome activation: recent advances and novel insights. *Trends Cell. Biol.* 25, 308–315 (2015).
82. Kanneganti TD, Lamkanfi M, Kim YG *et al.* Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. *Immunity* 26, 433–443 (2007).
83. Goldmann O, Sastalla I, Wos-Oxley M, Rohde M, Medina E. *Streptococcus pyogenes* induces oncosis in macrophages through the activation of an inflammatory programmed cell death pathway. *Cell. Microbiol.* 11, 138–155 (2009).

84. Coye LH, Collins CM. Identification of SpyA, a novel ADP-ribosyltransferase of *Streptococcus pyogenes*. *Mol. Microbiol.* 54, 89–98 (2004).
85. Hoff JS, DeWald M, Moseley SL, Collins CM, Voyich JM. SpyA a C3-like ADP-ribosyltransferase, contributes to virulence in a mouse subcutaneous model of *Streptococcus pyogenes* infection. *Infect. Immun.* 79, 2404–2411 (2011).
86. Korotkova N, Hoff JS, Becker DM, Quinn JK, Icenogle LM, Moseley SL. SpyA is a membrane-bound ADP-ribosyltransferase of *Streptococcus pyogenes* which modifies a streptococcal peptide, SpyB. *Mol. Microbiol.* 83, 936–952 (2012).
87. Bose S, Segovia JA, Somarajan SR, Chang TH, Kannan TR, Baseman JB. ADP-ribosylation of NLRP3 by *Mycoplasma pneumoniae* CARDS toxin regulates inflammasome activity. *MBio* 5(6), e02186-14 (2014).
88. Kayagaki N, Stowe IB, Lee BL *et al.* Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature* 526, 666–671 (2015).
- **A forward genetic screen leads to the discovery that caspase-11 cleaves gasdermin D, releasing its amino-terminal fragment to stimulate NLRP3-dependent caspase-1 activation, IL-1 β processing and cell membrane disruption in pyroptosis.**
89. Shi J, Zhao Y, Wang K *et al.* Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature* 526, 660–665 (2015).
90. He WT, Wan H, Hu L *et al.* Gasdermin D is an executor of pyroptosis and required for interleukin-1 β secretion. *Cell Res.* 25, 1285–1298 (2015).
91. Taabazuing CY, Okondo MC, Bachovchin DA. Pyroptosis and apoptosis pathways engage in bidirectional crosstalk in monocytes and macrophages. *Cell Chem. Biol.* 24, 507e504–514e504 (2017).
92. Severin A, Nickbarg E, Wooters J *et al.* Proteomic analysis and identification of *Streptococcus pyogenes* surface-associated proteins. *J. Bacteriol.* 189, 1514–1522 (2007).
93. Oehmcke S, Shannon O, Morgelin M, Herwald H. Streptococcal M proteins and their role as virulence determinants. *Clin. Chim. Acta* 411, 1172–1180 (2010).
94. Sanderson-Smith M, De Oliveira DM, Guglielmini J, *et al.*, A systematic and functional classification of *Streptococcus pyogenes* that serves as a new tool for molecular typing and vaccine development. *J. Infect. Dis.* 210, 1325–1338 (2014).
95. Aziz RK, Kotb M. Rise and persistence of global M1T1 clone of *Streptococcus pyogenes*. *Emerg. Infect. Dis.* 14, 1511–1517 (2008).
96. Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. *Lancet Infect. Dis.* 9, 611–616 (2009).
97. Zhu L, Olsen RJ, Nasser W *et al.* A molecular trigger for intercontinental epidemics of group A *Streptococcus*. *J. Clin. Invest.* 125, 3545–3559 (2015).
- **Analysis of more than 3600 M1 GAS genomes identified a recombination event and allelic variation in the chromosomal region encoding NADase and streptolysin O coinciding with increased toxin production and enhanced infection severity seen in the global M1 pandemic.**
98. Herwald H, Cramer H, Mörgelin M *et al.* M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. *Cell* 116, 367–379 (2004).
99. Macheboeuf P, Buffalo C, Fu CY *et al.* Streptococcal M1 protein constructs a pathological host fibrinogen network. *Nature* 472, 64–68 (2011).
100. McNamara C, Zinkernagel AS, Macheboeuf P *et al.* Coiled-coil irregularities and instabilities in group A *Streptococcus* M1 are required for virulence. *Science* 319, 1405–1408 (2008).
101. Soehnlein O, Oehmcke S, Ma X *et al.* Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein. *Eur. Respir. J.* 32, 405–412 (2008).
102. Akesson P, Schmidt KH, Cooney J, Björck L. M1 protein and protein H: IgGfC- and albumin-binding streptococcal surface proteins encoded by adjacent genes. *BioChem. J.* 300(Pt 3), 877–886 (1994).
103. Munoz-Planillo R, Kuffa P, Martínez-Colón G *et al.* K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. *Immunity* 38, 1142–1153 (2013).
104. Aziz RK. Invasive M1T1 Group A *Streptococcus* undergoes a phase-shift *in vivo* to prevent proteolytic degradation of multiple virulence factors by SpeB. *Mol. Microbiol.* 51, 123–134 (2004).
105. Nelson DC, Garbe J, Collin M. Cysteine proteinase SpeB from *Streptococcus pyogenes* - a potent modifier of immunologically important host and bacterial proteins. *Biol. Chem.* 392, 1077–1088 (2011).
106. Kansal RG, McGeer A, Low DE, Norrby-Teglund A, Kotb M. Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. *Infect. Immun.* 68, 6362–6369 (2000).
107. Maamary PG, Sanderson-Smith ML, Aziz RK *et al.* Parameters governing invasive disease propensity of non-M1 serotype Group A Streptococci. *J. Innate Immun.* 2, 596–606 (2010).

108. Sumbly P, Whitney AR, Graviss EA, DeLeo FR, Musser JM. Genome-wide analysis of group A streptococci reveals a mutation that modulates global phenotype and disease specificity. *PLoS Pathog.* 2, e5 (2006).
109. Chatellier S, Ihendyane N, Kansal RG *et al.* Genetic relatedness and superantigen expression in group A *Streptococcus* serotype M1 isolates from patients with severe and nonsevere invasive diseases. *Infect. Immun.* 68, 3523–3534 (2000).
110. Eriksson A, Norgren M. Cleavage of antigen-bound immunoglobulin G by SpeB contributes to streptococcal persistence in opsonizing blood. *Infect. Immun.* 71, 211–217 (2003).
111. Fischetti VA, Dale JB. One more disguise in the stealth behavior of *Streptococcus pyogenes*. *MBio* 7, e00661–16 (2016).
112. Osterlund A, Popa R, Nikkila T, Scheynius A, Engstrand L. Intracellular reservoir of *Streptococcus pyogenes* *in vivo*: a possible explanation for recurrent pharyngotonsillitis. *Laryngoscope* 107, 640–647 (1997).
113. Spinaci C, Magi G, Valardo PE, Facinelli B. Persistence of erythromycin-resistant group A streptococci in cultured respiratory cells. *Pediatr. Infect. Dis. J.* 25, 880–883 (2006).
114. Medina E, Rohde M, Chhatwal GS. Intracellular survival of *Streptococcus pyogenes* in polymorphonuclear cells results in increased bacterial virulence. *Infect. Immun.* 71, 5376–5380 (2003).
115. Bastiat-Sempe B, Love JF, Lomayesva N, Wessels MR. Streptolysin O and NAD-glycohydrolase prevent phagolysosome acidification and promote group A *Streptococcus* survival in macrophages. *MBio* 5, e01690–e01614 (2014).
- **GAS are internalized by macrophage phagocytosis but resist killing by damaging the phagolysosome membrane with streptolysin O, preventing phagolysosome acidification, and translocating NADase into the macrophage cytosol, where it augments streptolysin O-mediated cytotoxicity by depleting cellular energy stores.**
116. Herten E, Johansson L, Wallin R *et al.* M1 protein-dependent intracellular trafficking promotes persistence and replication of *Streptococcus pyogenes* in macrophages. *J. Innate Immun.* 2, 534–545 (2010).
117. Thulin P, Johansson L, Low DE *et al.* Viable Group A Streptococci in macrophages during acute soft tissue infection. *PLoS Med.* 3, e53 (2006).
118. Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. *J. Immunol.* 181, 3733–3739 (2008).
119. Veckman V, Miettinen M, Matikainen S *et al.* Lactobacilli and streptococci induce inflammatory chemokine production in human macrophages that stimulates Th1 cell chemotaxis. *J. Leukoc. Biol.* 74, 395–402 (2003).
120. Goldmann O, von Köckritz-Blickwede M, Hölzle C, Chhatwal GS, Geffers R, Medina E. Transcriptome analysis of murine macrophages in response to infection with *Streptococcus pyogenes* reveals an unusual activation program. *Infect. Immun.* 75, 4148–4157 (2007).
121. Porta C, Rimoldi M, Raes G *et al.* Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κ B. *Proc. Natl Acad. Sci. USA* 106, 14978–14983 (2009).
122. Hakansson A, Bentley CC, Shakhnovic EA, Wessels MR. Cytolysin-dependent evasion of lysosomal killing. *Proc. Natl Acad. Sci. USA* 102, 5192–5197 (2005).
123. Staali L, Morgelin M, Björck L, Tapper H. *Streptococcus pyogenes* expressing M and M-like surface proteins are phagocytosed but survive inside human neutrophils. *Cell. Microbiol.* 5, 253–265 (2003).
124. Osterlund A, Engstrand L. An intracellular sanctuary for *Streptococcus pyogenes* in human tonsillar epithelium—studies of asymptomatic carriers and *in vitro* cultured biopsies. *Acta Otolaryngol.* 117, 883–888 (1997).
125. Logsdon LK, Hakansson AP, Cortes G, Wessels MR. Streptolysin O inhibits clathrin-dependent internalization of group A *Streptococcus*. *MBio* 2, e00332–00310 (2011).
126. O'Seaghdha M, Wessels MR. Streptolysin O and its co-toxin NAD-glycohydrolase protect Group A *Streptococcus* from xenophagic killing. *PLoS Pathog.* 9, e1003394 (2013).
127. Ikebe T, Ato M, Matsumura T *et al.* Highly frequent mutations in negative regulators of multiple virulence genes in Group A streptococcal toxic shock syndrome isolates. *PLoS Pathog.* 6, e1000832 (2010).
128. Tran-Winkler HJ, Love JF, Gryllos I, Wessels MR. Signal transduction through CsrRS confers an invasive phenotype in group A *Streptococcus*. *PLoS Pathog.* 7, e1002361 (2011).
129. Trevino J, Perez N, Ramirez-Peña E *et al.* CovS simultaneously activates and inhibits the CovR-mediated repression of distinct subsets of group A *Streptococcus* virulence factor-encoding genes. *Infect. Immun.* 77, 3141–3149 (2009).
130. O'Neill AM, Thurston TL, Holden DW. Cytosolic replication of group A *Streptococcus* in human macrophages. *MBio* 7, e00020–00016 (2016).
- **Streptolysin O allows GAS to escape vacuoles and replicate in the cytosol of viable human macrophages, despite recruitment of autophagy receptors to the bacterium.**
131. Cuervo AM. Autophagy: in sickness and in health. *Trends Cell. Biol.* 14, 70–77 (2004).
132. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. *Dev. Cell* 6, 463–477 (2004).
133. Mizushima N. Autophagy: process and function. *Genes Dev.* 21, 2861–2873 (2007).

134. Mizushima N, Klionsky DJ. Protein turnover via autophagy: implications for metabolism. *Annu. Rev. Nutr.* 27, 19–40 (2007).
135. Huang J, Brummell JH. Autophagy in immunity against intracellular bacteria. *Curr. Top. Microbiol. Immunol.* 335, 189–215 (2009).
136. Mestre MB, Colombo MI. Autophagy and toxins: a matter of life or death. *Curr. Mol. Med.* 13, 241–251 (2013).
137. Joubert PE, Meiffren G, Grégoire IP *et al.* Autophagy induction by the pathogen receptor CD46. *Cell Host Microbe* 6, 354–366 (2009).
138. Nakagawa I, Amano A, Mizushima N *et al.* Autophagy defends cells against invading group A *Streptococcus*. *Science* 306, 1037–1040 (2004).
139. Kuang E, Okumura CY, Sheffy-Levin S *et al.* Regulation of ATG4B stability by RNF5 limits basal levels of autophagy and influences susceptibility to bacterial infection. *PLoS Genet.* 8, e1003007 (2012).
140. Sakurai A, Maruyama F, Funao J *et al.* Specific behavior of intracellular *Streptococcus pyogenes* that has undergone autophagic degradation is associated with bacterial streptolysin O and host small G proteins Rab5 and Rab7. *J. Biol. Chem.* 285, 22666–22675 (2010).
141. Yamaguchi H, Nakagawa I, Yamamoto A, Amano A, Noda T, Yoshimori T. An initial step of GAS-containing autophagosome-like vacuoles formation requires Rab7. *PLoS Pathog.* 5, e1000670 (2009).
142. Nozawa T, Aikawa C, Goda A, Maruyama F, Hamada S, Nakagawa I. The small GTPases Rab9A and Rab23 function at distinct steps in autophagy during Group A *Streptococcus* infection. *Cell. Microbiol.* 14, 1149–1165 (2012).
143. Thurston TL, Ryzhakov G, Bloor S, von Muhlinen N, Randow F. The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. *Nat. Immunol.* 10, 1215–1221 (2009).
144. Barnett TC, Liebl D, Seymour LM. The globally disseminated M1T1 clone of group A *Streptococcus* evades autophagy for intracellular replication. *Cell Host Microbe* 14, 675–682 (2013).
- **GAS avoids ubiquitylation and recognition by LC3 and the host autophagy machinery by degrading ubiquitin-LC3 adaptor proteins NDP52, p62 and NBR1.**
145. Sanjuan MA, Dillon CP, Tait SW. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. *Nature* 450, 1253–1257 (2007).
146. Shui W, Sheu L, Liu J. Membrane proteomics of phagosomes suggests a connection to autophagy. *Proc. Natl Acad. Sci. USA* 105, 16952–16957 (2008).
147. Cadwell K, Philips JA. Autophagy meets phagocytosis. *Immunity* 39, 425–427 (2013).